DPP4 and Hyperglycemia: As illustrated in Figure 1, DPPIV’s enzymatic activity reduces GLP-1 levels, exacerbating hyperglycemia, which, alongside the SARS-CoV-2-induced cytokine storm, leads to endothelial dysfunction, increased microthrombi, and heightened cerebrovascular risks.